Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glutamate Carboxypeptidase II | 2 | 2018 | 77 | 1.150 |
Why?
|
| Receptors, Metabotropic Glutamate | 5 | 2023 | 212 | 0.920 |
Why?
|
| Radiopharmaceuticals | 7 | 2023 | 2662 | 0.820 |
Why?
|
| Positron-Emission Tomography | 13 | 2023 | 6274 | 0.630 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2018 | 65 | 0.620 |
Why?
|
| Glutamates | 1 | 2018 | 398 | 0.570 |
Why?
|
| Urea | 1 | 2018 | 451 | 0.540 |
Why?
|
| Lysine | 1 | 2018 | 1008 | 0.450 |
Why?
|
| Radioactive Tracers | 2 | 2022 | 73 | 0.400 |
Why?
|
| Antigens, Surface | 1 | 2015 | 1663 | 0.390 |
Why?
|
| Potassium Channels | 2 | 2021 | 563 | 0.310 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 3769 | 0.290 |
Why?
|
| 4-Aminopyridine | 2 | 2022 | 81 | 0.260 |
Why?
|
| Kv1.2 Potassium Channel | 1 | 2022 | 15 | 0.220 |
Why?
|
| Kv1.1 Potassium Channel | 1 | 2022 | 29 | 0.220 |
Why?
|
| Pyrans | 1 | 2022 | 53 | 0.200 |
Why?
|
| Picolinic Acids | 1 | 2022 | 53 | 0.200 |
Why?
|
| Fluorine Radioisotopes | 2 | 2023 | 449 | 0.190 |
Why?
|
| Cromolyn Sodium | 1 | 2021 | 87 | 0.190 |
Why?
|
| Gallium Radioisotopes | 2 | 2018 | 178 | 0.180 |
Why?
|
| Demyelinating Diseases | 1 | 2022 | 363 | 0.180 |
Why?
|
| Tissue Distribution | 3 | 2021 | 2335 | 0.170 |
Why?
|
| Ligands | 4 | 2022 | 3294 | 0.170 |
Why?
|
| Drug Stability | 1 | 2018 | 291 | 0.150 |
Why?
|
| Isoquinolines | 1 | 2019 | 368 | 0.150 |
Why?
|
| Neuralgia | 1 | 2023 | 572 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2020 | 542 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 11074 | 0.140 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 8037 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2022 | 2220 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2022 | 831 | 0.130 |
Why?
|
| Cysteamine | 1 | 2014 | 23 | 0.130 |
Why?
|
| Rhenium | 1 | 2014 | 13 | 0.130 |
Why?
|
| Ethiodized Oil | 1 | 2014 | 33 | 0.130 |
Why?
|
| Nanocapsules | 1 | 2015 | 91 | 0.120 |
Why?
|
| Ferric Compounds | 1 | 2015 | 374 | 0.120 |
Why?
|
| Magnetite Nanoparticles | 1 | 2015 | 321 | 0.110 |
Why?
|
| Radioisotopes | 1 | 2014 | 499 | 0.110 |
Why?
|
| Coordination Complexes | 1 | 2014 | 115 | 0.110 |
Why?
|
| Brain | 8 | 2023 | 26413 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2022 | 8302 | 0.110 |
Why?
|
| Microglia | 1 | 2021 | 1266 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 2017 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 35423 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 6386 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2018 | 3689 | 0.100 |
Why?
|
| Macaca mulatta | 3 | 2023 | 2378 | 0.100 |
Why?
|
| Animals | 16 | 2023 | 168788 | 0.100 |
Why?
|
| Contrast Media | 2 | 2022 | 5300 | 0.090 |
Why?
|
| Rats | 6 | 2022 | 24273 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 16687 | 0.090 |
Why?
|
| tau Proteins | 1 | 2019 | 1868 | 0.090 |
Why?
|
| Macaca fascicularis | 2 | 2022 | 910 | 0.090 |
Why?
|
| Phenylpropionates | 1 | 2008 | 30 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2020 | 2025 | 0.080 |
Why?
|
| Radiochemistry | 2 | 2021 | 58 | 0.080 |
Why?
|
| Drug Design | 2 | 2014 | 1078 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3557 | 0.080 |
Why?
|
| PPAR alpha | 1 | 2008 | 196 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2008 | 493 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2004 | 371 | 0.070 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2004 | 29 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2015 | 1905 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3469 | 0.060 |
Why?
|
| Diterpenes | 1 | 2004 | 173 | 0.060 |
Why?
|
| Cricetulus | 1 | 2022 | 817 | 0.050 |
Why?
|
| Permeability | 1 | 2022 | 738 | 0.050 |
Why?
|
| Carbon Radioisotopes | 1 | 2022 | 592 | 0.050 |
Why?
|
| Mitochondria, Heart | 1 | 2022 | 247 | 0.050 |
Why?
|
| Automation | 1 | 2023 | 584 | 0.050 |
Why?
|
| Haplorhini | 1 | 2021 | 552 | 0.050 |
Why?
|
| Primates | 1 | 2022 | 544 | 0.040 |
Why?
|
| Mice | 5 | 2021 | 81178 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2004 | 1726 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 4252 | 0.040 |
Why?
|
| Cricetinae | 1 | 2022 | 2472 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2023 | 986 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2022 | 692 | 0.040 |
Why?
|
| Male | 8 | 2022 | 350027 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2022 | 1016 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2021 | 1538 | 0.030 |
Why?
|
| Surface-Active Agents | 1 | 2015 | 159 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 2279 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 941 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 282 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2014 | 243 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2022 | 1637 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2023 | 2732 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20123 | 0.030 |
Why?
|
| Cell Line | 2 | 2021 | 15999 | 0.020 |
Why?
|
| Particle Size | 1 | 2015 | 1642 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 665 | 0.020 |
Why?
|
| Humans | 6 | 2023 | 744220 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2021 | 19227 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5096 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 21824 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2021 | 3585 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 625 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2008 | 216 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3591 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 1392 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2008 | 1907 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 329 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 18027 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 3133 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 1782 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 626 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 320 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 611 | 0.010 |
Why?
|
| Edema | 1 | 2004 | 790 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14726 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2008 | 5458 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 19907 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2004 | 2131 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 57768 | 0.010 |
Why?
|
| Female | 2 | 2022 | 380197 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 163253 | 0.000 |
Why?
|
| Middle Aged | 1 | 2019 | 213367 | 0.000 |
Why?
|
Concepts
(118)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(28)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_